RecruitingNCT04101968

The GBA Multimodal Study in Parkinson's Disease

Multimodal Molecular Imaging and Biometric Analysis in GBA-PD and Asymptomatic GBA-mutation Carriers

Sponsor

Pacific Parkinson's Research Centre

Enrollment

25 participants

Start Date

May 1, 2019

Study Type

OBSERVATIONAL

Conditions

Gaucher Disease Parkinson Disease GBA Gene Mutation

Summary

This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how a specific genetic change (called a GBA mutation) affects the brain and body in people with Parkinson's disease. Researchers are using brain scans and other tests to better understand this type of Parkinson's. **You may be eligible if...** - You carry a specific genetic change in the GBA gene (such as p.L444P or p.N370S) - You are between 18 and 80 years old **You may NOT be eligible if...** - You have another neurological disorder in addition to Parkinson's - You have a pacemaker or metal implants that prevent MRI scans - You have severe claustrophobia - You are unable to temporarily stop your Parkinson's medications - You are currently taking cholinergic (nerve-stimulating) drugs Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.